Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 2091-2100 Newer>

BusinessWeek June 20, 2005 Spencer E. Ante	Powering Through Clogged Arteries FoxHollow's SilverHawk is a promising alternative to stents and bypass surgery.
The Motley Fool June 10, 2005 T.G. Wolf	Greatbatch Finds a Pulse Can this specialist in medical devices be great for investors again?
The Motley Fool June 10, 2005 Brian Gorman	PAREXEL's New Risk The contract pharmaceutical research services provider is realigning its business, but even with reduced U.S. operations, it faces increased risk. Investors, beware.
The Motley Fool June 10, 2005 Stephen D. Simpson	The High Cost of Diabetes Settling claims related to Zyprexa was probably the best of a bad set of choices for Eli Lilly. Investors need to remember to incorporate this as a risk factor for all drug companies.
Nutra Solutions June 1, 2005	Hidden Drug Costs Up to five salespeople from the same company may call on the same doctor about the same product. Drug makers spend over $7 billion on such calls each year, compared to $4 billion on direct-to-consumer advertising.
Pharmaceutical Executive May 1, 2005 Joanna Breitstein	Eisai's New Leadership Japanese pharmaceutical Eisai's US president and COO Lonnel Coats, and chairman and CEO Hajime Shimizu, talk about their first year on the job.
Pharmaceutical Executive May 1, 2005 Erik Felker	Elephant or Specialist? The Bush Administration has put in place the groundwork for new market forces that will forever change how pharmaceuticals are commercialized. Although the long-term impact of this change is not known, unprepared companies are at a serious disadvantage.
Pharmaceutical Executive May 1, 2005 L.J. Sellers	It's All About Immunity Hollis-Eden is developing drugs that help the body fight foreign attackers -- including radiation. Other companies are in competition to bring new autoimmune drugs to the market, but Hollis-Eden believes its compounds will be significantly more effective
Pharmaceutical Executive May 1, 2005 Richard Gliklich	Forget Selecting a Site --- Now the Site Selects You The competition for where to conduct Phase IV trials is rewriting the rules of site selection for pharmaceuticals.
Pharmaceutical Executive May 1, 2005 Renda & Moyer	Superstar Selection Take your time interviewing and hiring your next rep - it will pay off for years to come. Remember, new hires are a representation of you, your company, and the entire pharmaceutical industry.
<Older 2091-2100 Newer> Return to current articles.